Progesterone for Preterm Birth Prevention

Obstetrics and Gynecology Clinics of North America

Volumn 39, Issue 1, 2012, Pages 1-16

  Ransom, Carla E ^a   Murtha, Amy P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

17 Hydroxyprogesterone caproate; Prematurity; Preterm birth; Progesterone; Progestin

Indexed keywords

COLLAGEN TYPE 1; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYCLOOXYGENASE 2; GESTAGEN; HYDROXYPROGESTERONE CAPROATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 8; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR;

CERVICAL LENGTH MEASUREMENT; CHEMOPROPHYLAXIS; CONGENITAL MALFORMATION; COST OF ILLNESS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FETUS ECHOGRAPHY; HEALTH CARE COST; HORMONE ACTION; HOSPITAL CARE; HUMAN; INJECTION SITE REACTION; MULTIPLE PREGNANCY; NONHUMAN; OUTPATIENT CARE; PATIENT SELECTION; PREGNANCY DIABETES MELLITUS; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; STILLBIRTH; UNSPECIFIED SIDE EFFECT; URTICARIA; UTERINE CERVIX CERCLAGE; UTERUS CONTRACTILITY; VAGINA DISCHARGE; VAGINA PESSARY;

CERVIX UTERI; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT MORTALITY; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY, HIGH-RISK; PREMATURE BIRTH; PROGESTERONE; PROGESTINS; UNITED STATES;

EID: 84857424150     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2011.12.004     Document Type: Review

References (78)

1. Mathews T.J., MacDorman M.F. Infant mortality statistics from the 2005 period linked birth/infant death data set. Natl Vital Stat Rep 2008, 57(2):1-32.
2. Martin J.A., Hamilton B.E., Sutton P.D., et al. Births: final data for 2007. Natl Vital Stat Rep 2010, 58(24):1-85.
3. Hamilton B.E., Martin J.A., Ventura S.J. Births: Preliminary data for 2009. National Vital Statistics Report 2010, 59(3):1-29.
4. Koppe J., Ilsen A. Long-term outcome 1998, Parthenon Publishing, London.
5. Final natality data 2008, Centers for Disease Control and Prevention, National Center for Health StatisticsNational Center for Health Statistics, National Center for Health Statistics, Hyattsville (MD).
6. Morrison J.C. Preterm birth: a puzzle worth solving. Obstet Gynecol 1990, 76(Suppl I):5S-12S.
7. Swamy G.K., Ostbye T., Skjaerven R. Association of preterm birth with long-term survival, reproduction, and next-generation preterm birth. JAMA 2008, 299(12):1429-1436.
8. Beck S., Wojdyla D., Say L., et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ 2010, 88(1):31-38.
9. Joseph K.S., Kramer M.S., Marcoux S., et al. Determinants of preterm birth rates in Canada from 1981 through 1983 and from 1992 through 1994. N Engl J Med 1998, 339(20):1434-1439.
10. Dodd J.M., Crowther C.A., McPhee A.J., et al. Progesterone after previous preterm birth for prevention of neonatal respiratory distress syndrome (PROGRESS): a randomised controlled trial. BMC Pregnancy Childbirth 2009, 9:6.
11. Moutquin J.M. Classification and heterogeneity of preterm birth. BJOG 2003, 110(Suppl 20):30-33.
12. Sfakianaki A.K., Norwitz E.R. Mechanisms of progesterone action in inhibiting prematurity. J Matern Fetal Neonatal Med 2006, 19(12):763-772.
13. Hegele-Hartung C., Chwalisz K., Beier H.M., et al. Ripening of the uterine cervix of the guinea-pig after treatment with the progesterone antagonist onapristone (ZK 98.299): an electron microscopic study. Hum Reprod 1989, 4(4):369-377.
14. Ruddock N.K., Shi S.Q., Jain S., et al. Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol 2008, 199(4):e391-e397.
15. Csapo A. Progesterone block. Am J Anat 1956, 98(2):273-291.
16. Allport V.C., Pieber D., Slater D.M., et al. Human labour is associated with nuclear factor-kappaB activity which mediates cyclo-oxygenase-2 expression and is involved with the 'functional progesterone withdrawal'. Mol Hum Reprod 2001, 7(6):581-586.
17. Hardy D.B., Janowski B.A., Corey D.R., et al. Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression. Mol Endocrinol 2006, 20(11):2724-2733.
18. Condon J.C., Jeyasuria P., Faust J.M., et al. A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. Proc Natl Acad Sci USA 2003, 100(16):9518-9523.
19. Marx S.G., Wentz M.J., Mackay L.B., et al. Effects of progesterone on iNOS, COX-2, and collagen expression in the cervix. J Histochem Cytochem 2006, 54(6):623-639.
20. Xu H., Gonzalez J.M., Ofori E., et al. Preventing cervical ripening: the primary mechanism by which progestational agents prevent preterm birth?. Am J Obstet Gynecol 2008, 198(3):e311-e318.
21. Rajabi M.R., Dodge G.R., Solomon S., et al. Immunochemical and immunohistochemical evidence of estrogen-mediated collagenolysis as a mechanism of cervical dilatation in the guinea pig at parturition. Endocrinology 1991, 128(1):1-8. 314.
22. Ito A., Imada K., Sato T., et al. Suppression of interleukin 8 production by progesterone in rabbit uterine cervix. Biochem J 1994, 301(Pt 1):183-186.
23. Foglia L.M., Ippolito D.L., Stallings J.D., et al. Intramuscular 17alpha-hydroxyprogesterone caproate administration attenuates immunoresponsiveness of maternal peripheral blood mononuclear cells. Am J Obstet Gynecol 2010, 203(6). 561,e1-5.
24. Murtha A.P., Feng L., Yonish B., et al. Progesterone protects fetal chorion and maternal decidua cells from calcium-induced death. Am J Obstet Gynecol 2007, 196(3):257.e1-257.e5.
25. Cakmak H., Schatz F., Huang S.T., et al. Progestin suppresses thrombin- and interleukin-1beta-induced interleukin-11 production in term decidual cells: implications for preterm delivery. J Clin Endocrinol Metab 2005, 90(9):5279-5286.
26. McLean M., Bisits A., Davies J., et al. A placental clock controlling the length of human pregnancy. Nat Med 1995, 1(5):460-463.
27. Challis J.R., Sloboda D.M., Alfaidy N., et al. Prostaglandins and mechanisms of preterm birth. Reproduction 2002, 124(1):1-17.
28. Jeschke U., Mylonas I., Richter D.U., et al. Regulation of progesterone production in human term trophoblasts in vitro by CRH, ACTH and cortisol (prednisolone). Arch Gynecol Obstet 2005, 272(1):7-12.
29. Karalis K., Goodwin G., Majzoub J.A. Cortisol blockade of progesterone: a possible molecular mechanism involved in the initiation of human labor. Nat Med 1996, 2(5):556-560.
30. Levine L. Habitual abortion: a controlled study of progestational therapy. West J Surg Obstet Gynecol 1964, 72:30-36.
31. Johnson J.W., Austin K.L., Jones G.S., et al. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975, 293(14):675-680.
32. Meis P.J., Klebanoff M., Thom E., et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003, 348(24):2379-2385.
33. Da Fonseca E.B., Bittar R.E., Carvalho M.H., et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003, 188(2):419-424.
34. O'Brien J.M., Adair C.D., Lewis D.F., et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007, 30(5):687-696.
35. Briery C.M., Veillon E.W., Klauser C.K., et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am J Obstet Gynecol 2011, 204(1):54.e1-54.e5.
36. Briery C.M., Veillon E.W., Klauser C.K., et al. Progesterone does not prevent preterm births in women with twins. South Med J 2009, 102(9):900-904.
37. Hartikainen-Sorri A.L., Kauppila A., Tuimala R. Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980, 56(6):692-695.
38. Norman J.E., Mackenzie F., Owen P., et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet 2009, 373(9680):2034-2040.
39. Rouse D.J., Caritis S.N., Peaceman A.M., et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007, 357(5):454-461.
40. Caritis S.N., Rouse D.J., Peaceman A.M., et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 2009, 113(2 Pt 1):285-292.
41. Combs C.A., Garite T., Maurel K., et al. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 2010, 203(3):248.e1-248.e9.
42. Iams J.D., Goldenberg R.L., Meis P.J., et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med 1996, 334(9):567-572.
43. Mercer B.M., Goldenberg R.L., Moawad A.H., et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999, 181(5 Pt 1):1216-1221.
44. DeFranco E.A., O'Brien J.M., Adair C.D., et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007, 30(5):697-705.
45. O'Brien J.M., Defranco E.A., Adair C.D., et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2009, 34(6):653-659.
46. Fonseca E.B., Celik E., Parra M., et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007, 357(5):462-469.
47. Hassan S.S., Romero R., Vidyadhari D., et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011, 38(1):18-31.
48. Owen J., Hankins G., Iams J.D., et al. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. Am J Obstet Gynecol 2009, 201(4):375.e1-375.e8.
49. Keeler S.M., Kiefer D., Rochon M., et al. A randomized trial of cerclage vs. 17 alpha-hydroxyprogesterone caproate for treatment of short cervix. J Perinat Med 2009, 37(5):473-479.
50. Berghella V., Figueroa D., Szychowski J.M., et al. 17-Alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol 2010, 202(4):351.e1-351.e6.
51. Durnwald C.P., Momirova V., Rouse D.J., et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-alpha hydroxyprogesterone caproate. J Matern Fetal Neonatal Med 2010, 23(12):1360-1364.
52. Facchinetti F., Paganelli S., Comitini G., et al. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007, 196(5):453.e1-453.e4. [discussion: 421].
53. Use of progesterone to reduce preterm birth. Obstet Gynecol 2008, 112(4):963-965. ACOG Committee Opinion no. 419 October 2008 (replaces no. 291, November 2003).
54. Gonzalez-Quintero V.H., de la Torre L., Rhea D.J., et al. Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice. Am J Obstet Gynecol 2010, 203(3). 257,e1-5.
55. Rai P., Rajaram S., Goel N., et al. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 2009, 104(1):40-43.
56. Glover M.M., McKenna D.S., Downing C.M., et al. A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. Am J Perinatol 2011, 28(5):377-381.
57. Majhi P., Bagga R., Kalra J., et al. Intravaginal use of natural micronised progesterone to prevent pre-term birth: a randomised trial in India. J Obstet Gynaecol 2009, 29(6):493-498.
58. Bulletti C., de Ziegler D., Flamigni C., et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod 1997, 12(5):1073-1079.
59. Cicinelli E., de Ziegler D., Bulletti C., et al. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000, 95(3):403-406.
60. De Ziegler D., Bulletti C., De Monstier B., et al. The first uterine pass effect. Ann NY Acad Sci 1997, 828:291-299.
61. Cicinelli E., Borraccino V., Petruzzi D., et al. Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Fertil Steril 1996, 65(4):860-862.
62. Mahaguna V., McDermott J.M., Zhang F., et al. Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Pharm 2004, 30(10):1069-1078.
63. Toner J.P. Vaginal delivery of progesterone in donor oocyte therapy. Hum Reprod 2000, 15(Suppl 1):166-171.
64. Silver R.M., Cunningham F.G. Deus ex Makena?. Obstet Gynecol 2011, 117(6):1263-1265.
65. Gonzalez-Quintero V.H., Istwan N.B., Rhea D.J., et al. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med 2007, 20(3):249-252.
66. How H.Y., Barton J.R., Istwan N.B., et al. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?. Am J Obstet Gynecol 2007, 197(3). 260,e1-4.
67. Rebarber A., Ferrara L.A., Hanley M.L., et al. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007, 196(3). 224,e1-4.
68. Ness A., Dias T., Damus K., et al. Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey. Am J Obstet Gynecol 2006, 195(4):1174-1179.
69. Petrini J.R., Callaghan W.M., Klebanoff M., et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005, 105(2):267-272.
70. Katz Z., Lancet M., Skornik J., et al. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol 1985, 65(6):775-780.
71. Resseguie L.J., Hick J.F., Bruen J.A., et al. Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974. Fertil Steril 1985, 43(4):514-519.
72. Yovich J.L., Turner S.R., Draper R. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology 1988, 38(2):135-144.
73. Dodd J.M., Flenady V.J., Cincotta R., et al. Progesterone for the prevention of preterm birth: a systematic review. Obstet Gynecol 2008, 112(1):127-134.
74. Branisteanu D.D., Mathieu C. Progesterone in gestational diabetes mellitus: guilty or not guilty?. Trends Endocrinol Metab 2003, 14(2):54-56.
75. Rebarber A., Istwan N.B., Russo-Stieglitz K., et al. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 2007, 30(9):2277-2280.
76. Waters T.P., Schultz B.A., Mercer B.M., et al. Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy. Obstet Gynecol 2009, 114(1):45-49.
77. Gyamfi C., Horton A.L., Momirova V., et al. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. Am J Obstet Gynecol 2009, 201(4). 392,e1-5.
78. Northen A.T., Norman G.S., Anderson K., et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007, 110(4):865-872.